Image de couverture de livre

Editorial: HBeAg ‐Positive Chronic Hepatitis B With Low HBsAg Levels—Exploring Clinical Significance of preS2 Deletion Mutations. Authors' Reply

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Yuxin Chen, Rui Huang, Chao Wu, Yong Liu
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Alimentary Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Editorial: HBeAg ‐Positive Chronic Hepatitis B With Low HBsAg Levels—Exploring Clinical Significance of preS2 Deletion Mutations
par: Ying‐Nan Tsai, et autres
Publié: (2025)

Virological and Immunological Characteristics of HBeAg ‐Positive Chronic Hepatitis B Patients With Low HBsAg Levels
par: Yuxin Chen, et autres
Publié: (2024)

Favourable Prognosis of Patients With Untreated HBeAg‐Negative Chronic Hepatitis B Virus Infection With HBsAg < 100 IU/mL
par: Jian Wang, et autres
Publié: (2024)

Editorial: Ultralow HBsAg Levels and the Prediction of Cure in Chronic Hepatitis B—Authors' Reply
par: Jian Wang, et autres
Publié: (2025)

Letter: Association of persistently high HBsAg levels during HBeAg‐seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients
par: Jian Wang, et autres
Publié: (2024)

Higher end‐of‐treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg‐negative chronic hepatitis B patients stopping antivirals
par: Yen‐Chun Liu, et autres
Publié: (2024)

Serum sPD‐1 and sPD‐L1 as predictive biomarkers for HBsAg clearance in HBeAg‐negative CHB patients undergoing IFN‐based therapy
par: Xiyao Chen, et autres
Publié: (2024)

Letter: Muddle of serum sPD‐1 and sPD‐L1 levels and association with HBsAg clearance in HBeAg‐negative CHB patients on IFN therapy
par: Ankur Jindal
Publié: (2024)

Editorial: Using HBcrAg and HBsAg Kinetics to Optimise Monitoring After Nucleo(s)tide Analogue Withdrawal. Authors' Reply
par: Yasuhito Tanaka, et autres
Publié: (2026)

Letter: No Biochemical Relapse Is Associated With the Highest Off‐Therapy HBsAg Loss Rate—Authors' Reply
par: Ying‐Nan Tsai, et autres
Publié: (2025)

Dynamics of Circulatory HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation Using iTACT Assays to Predict Clinical Flares and HBsAg Loss
par: Ying‐Nan Tsai, et autres
Publié: (2026)

Letter: Positivity of High‐Sensitivity HBsAg Test Was Significantly Associated With Poor Prognosis in Patients With Non‐HBV‐Related HCC
par: Xiaosong Li, et autres
Publié: (2024)

Editorial: Using HBcrAg and HBsAg Kinetics to Optimise Monitoring After Nucleo(s)tide Analogue Withdrawal
par: Edo J. Dongelmans, et autres
Publié: (2026)

Letter: No Biochemical Relapse Is Associated With the Highest Off‐Therapy HBsAg Loss Rate
par: Wen‐Juei Jeng, et autres
Publié: (2025)

Letter: Dynamic HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation: Considerations in Interpreting Predictive Performance
par: Hsiang‐Ting Keng, et autres
Publié: (2026)

Positivity of high‐sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non‐HBV‐related HCC
par: Naohiro Yasuura, et autres
Publié: (2024)

CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance
par: Hye Won Lee, et autres
Publié: (2024)

Long‐Term Follow‐Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss
par: Simon J. Hume, et autres
Publié: (2025)

Editorial: High qHBsAg—Is it a good or bad signal? Authors' reply
par: Hsin‐Che Lin, et autres
Publié: (2024)

Letter: Advancing Serologic Classification in Indeterminate Chronic Hepatitis B Through Dynamic and Integrated Frameworks—Authors' Reply
par: Rui Huang, et autres
Publié: (2025)

Letter on ‘Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis’: Authors' Reply
par: Lukas Burghart, et autres
Publié: (2026)

Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C. Authors' Reply
par: Pei‐Chien Tsai, et autres
Publié: (2026)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
par: Francisco Idalsoaga, et autres
Publié: (2025)

Letter: “Tenofovir Alafenamide—The ‘Star of Potential’ for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials.” Authors' Reply
par: Maria Buti
Publié: (2025)

Meta‐Analysis: High anti‐ HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment
par: Shiva Poola, et autres
Publié: (2025)

Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’—Authors' Reply
par: Ning Yu, et autres
Publié: (2025)

Editorial: Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients With Metabolic Dysfunction—Do Existing Scores Clear the Bar? Authors' Reply
par: Lesley A. Patmore, et autres
Publié: (2025)

Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy—Authors' Reply
par: Tanat Saeoui, et autres
Publié: (2025)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
par: Nina Dominik, et autres
Publié: (2024)

Editorial: The Role of Liver Biopsy in ANA Positive Subjects. Authors' Reply
par: David Mehdi Asgher Niazi, et autres
Publié: (2026)

Editorial: Predicting Hepatocellular Cancer in Clinical Practice. Authors' Reply
par: Shuaibing Ying, et autres
Publié: (2026)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors—Authors' Reply
par: Ying‐Nan Tsai, et autres
Publié: (2025)

Letter: Drug‐Induced Autoimmune‐Like Hepatitis—A Trigger on the Disease Spectrum. Authors' Reply
par: Pinelopi Arvaniti, et autres
Publié: (2025)

Letter: Addressing Gaps in Hospital‐Based Hepatitis C Screening—Insights and Recommendations. Authors' Reply'
par: Alberto Ferrarese, et autres
Publié: (2025)

Editorial: Steroid‐Induced Diabetes in Autoimmune Hepatitis—A Call for Treatment Optimisation. Authors' Reply
par: Sarah Flatley
Publié: (2026)

Letter: Double PBC ‐Related Autoantibody Positivity—How Essential Is It for Diagnosis? Authors' Reply
par: Hong‐Li Liu, et autres
Publié: (2026)

Editorial: Low‐Level Viraemia in Chronic Hepatitis B—A Benign State or Missed Opportunity?
par: Miriam T. Levy
Publié: (2026)

Editorial: When Yeast Turns Beast—Unmasking an Overlooked Threat in Alcohol‐Related Hepatitis. Authors' Reply
par: Vincent Mallet, et autres
Publié: (2025)

Letter on ‘Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis’—Authors' Reply
par: Francisco Idalsoaga, et autres
Publié: (2025)

Increased Risk for Liver Disease in Patients With Chronic Hepatitis B Virus Infection and Low‐Level Viraemia
par: Paul Y. Kwo, et autres
Publié: (2026)